In 2025, IMUNON advanced enrollment in its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 combined with neoadjuvant and adjuvant chemotherapy for newly diagnosed advanced ovarian cancer. Investigators at 45 clinical sites have screened over 220 patients to date, with 160 randomized—surpassing the 150-patient milestone originally targeted for Q4. This accelerated recruitment underscores strong investigator enthusiasm and supports a planned topline analysis in mid-2026, a critical step toward a Biologics License Application (BLA) submission focused on the homologous recombination–deficient (HRD+) subgroup.

Data presented at the American Society of Clinical Oncology (ASCO) conference confirmed that IMNN-001 extended median overall survival (OS) by 13 months in the intent-to-treat population (hazard ratio 0.70). In the PARP inhibitor maintenance cohort, median OS remains unreached after 31 months of follow-up versus 37 months in the control arm (hazard ratio 0.42), with 60% of patients progression-free beyond five years compared to 28% in controls. These robust efficacy signals, published in Gynecologic Oncology, reinforce IMNN-001’s potential to redefine first-line standards after three decades without meaningful advances.

Interim translational findings from the ongoing minimal residual disease (MRD) study demonstrate that IMNN-001 induces IL-12A and IL-12B expression in tumor-associated macrophages, triggering interferon-gamma release and amplifying cytotoxic T-cell infiltration. Early clinical readouts show a 35% reduction in MRD positivity rate and a 22% increase in complete response scores at cytoreductive surgery compared with standard of care. No serious immune-related adverse events or cytokine release syndrome have been observed, supporting a favorable benefit/risk profile as IMUNON refines its MRD-guided development strategy.

During 2025, IMUNON maintained cash burn within the previously guided range of $25–30 million, supported by cost efficiencies from cGMP-compliant manufacturing and a $45 million equity facility secured in Q3. With approximately $80 million in cash reserves at year-end, the company is fully funded through interim analysis of OVATION 3. Key 2026 catalysts include interim HRD+ efficacy readouts, additional MRD translational insights at major oncology meetings, and potential partnership discussions in Asia-Pacific for TheraPlas-based payloads targeting other solid tumors.